Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab

• Published in: Dermatology Reports
• Main Authors: Angela Fico, Edoardo Mortato, Claudia Paganini, Marina Talamonti, Cosimo Di Raimondo, Dionisio Silvaggio, Luca Bianchi, Marco Galluzzo
• Format: Article
• Language: English
• Published: PAGEPress Publications 2025-05-01
• Subjects: Paradoxical psoriasis; generalized pustular psoriasis; adalimumab biosimilar; brodalumab
• Online Access: https://www.pagepress.org/journals/dr/article/view/10414
• ISSN: 2036-7392; 2036-7406

Paradoxical psoriasis is a rare but increasingly recognized adverse effect of anti-TNF-α therapy, characterized by the onset or exacerbation of psoriatic lesions in patients treated for other immune-mediated conditions. We report the case of a 47-year-old woman with chronic plaque psoriasis who developed severe generalized pustular psoriasis (GPP) after six months of treatment with an adalimumab biosimilar. Given the extent and severity of the eruption and following inadequate response to previous conventional therapies, the patient was treated with brodalumab, an IL-17RA inhibitor. Rapid and complete remission of both pustular and plaque psoriasis was achieved and maintained for over 60 weeks. This case supports the efficacy of IL-17 pathway blockade in managing paradoxical GPP and highlights the importance of prompt recognition and appropriate therapeutic switching in severe biologic-induced psoriasis.